BIOE Bio Essence Corp. Forecast, Technical & Fundamental Analysis

BIOE's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BIOE turned positive on December 01, 2025. Looking at past instances where BIOE's MACD turned positive, the stock continued to rise in of 13 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 05, 2025. You may want to consider a long position or call options on BIOE as a result. In of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BIOE moved out of overbought territory on December 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 10 similar instances where the indicator moved out of overbought territory. In of the 10 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 20 cases where BIOE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

BIOE moved below its 50-day moving average on December 24, 2025 date and that indicates a change from an upward trend to a downward trend.

The Aroon Indicator for BIOE entered a downward trend on December 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (21.577). P/E Ratio (0.000) is within average values for comparable stocks, (74.473). BIOE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.981). BIOE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (3.679) is also within normal values, averaging (64.586).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIOE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.